| Literature DB >> 34177280 |
Kun Xie1, Xiufang Gao1, Liwen Bao1, Ying Shan1, Haiming Shi1, Yong Li1.
Abstract
PURPOSE: We sought to investigate and improve the integrated management of hypertension in general and community hospitals in China. PATIENTS AND METHODS: We carried out a cross-sectional study in 90 centers from 15 cities in China from 2017 to 2018. Patients with primary hypertension were included.Entities:
Keywords: abdominal circumference; body mass index; diabetes; hypercholesterolemia; hypertension
Year: 2021 PMID: 34177280 PMCID: PMC8219293 DOI: 10.2147/RMHP.S306735
Source DB: PubMed Journal: Risk Manag Healthc Policy ISSN: 1179-1594
Figure 1The flow charts of the inclusion/exclusion steps of the cross-sectional study.
General Characteristics of Patients with Hypertension
| Total N=4286 | Female N=1885 | Male N=2401 | p | |
|---|---|---|---|---|
| Age | 64.81±12.71 | 65.87±11.59 | 63.98±13.46 | <0.001 |
| BMI | 24.88±4.04 | 24.68±4.40 | 25.05±3.72 | 0.003 |
| Abdominal circumference(cm) | 85.45±14.17 | 82.28±13.34 | 87.96±14.31 | <0.001 |
| Smoking | 14.3% | 1.6% | 24.3% | <0.001 |
| SBP (mmHg) | 141.65±17.35 | 141.44±17.70 | 141.81±17.08 | 0.49 |
| DBP (mmHg) | 83.45±11.88 | 82.46±11.71 | 84.23±11.95 | <0.001 |
| BP<140/90 mmHg (%) | 43.2% | 45.3% | 41.6% | 0.018 |
| BP<130/80 mmHg (%) | 11.5% | 13.5% | 10.0% | <0.001 |
| Antihypertensive therapy | 92.5% | 94.0% | 91.4% | <0.001 |
| TC (mmol/L) | 4.79±1.33 | 4.99±1.31 | 4.63±1.31 | <0.001 |
| LDL-C (mmol/L) | 2.84±1.13 | 2.98±1.27 | 2.72±0.97 | <0.001 |
| HDL-C (mmol/L) | 1.27±0.33 | 1.34±0.32 | 1.21±0.32 | <0.001 |
| TG (mmol/L) | 2.02±1.54 | 2.05±1.49 | 1.99±1.58 | 0.32 |
| Statin treatment | 54.8% | 56.3% | 53.5% | 0.09 |
| DM | 22.4% | 22.3% | 22.4% | 0.96 |
| CAD | 20.6% | 21.0% | 20.3% | 0.61 |
| CKD | 22.0% | 25.5% | 19.3% | <0.001 |
| eGFR | 79.24±29.18 | 75.13±26.92 | 82.48±30.47 | <0.001 |
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL-C, low density lipoprotein-C; HDL-C, high density lipoprotein-C; TG, triglyceride; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate.
Figure 2The control of BP and LDL-C in patients with hypertension. (A) The control rate of BP < 140/90 mmHg and BP <130/80 mmHg according to the age categories. (B) The control of LDL-C in hypertensive patients.
LDL-C Management in Patients with Concomitant CAD, Diabetes and CKD
| Non-CAD | CAD | p | Non-Diabetes | Diabetes | p | Non-CKD | CKD | p | |
|---|---|---|---|---|---|---|---|---|---|
| Smoking | 14.6% | 13.1% | 0.28 | 13.8% | 16.3% | 0.07 | 13.1% | 13.2% | 0.83 |
| BMI | 24.88±3.95 | 24.88±3.68 | 0.99 | 24.78±3.81 | 25.20±4.11 | 0.005 | 24.91±3.87 | 25.61±5.97 | 0.001 |
| Statin(%) | 47.4% | 79.8% | <0.001 | 50.7% | 66.2% | <0.001 | 58.2% | 67.1% | <0.001 |
| LDL-C (mmol/L) | <0.001 | 0.04 | <0.001 | ||||||
| <1.8 | 11.1% | 24.7% | 13.1% | 17.5% | 15.9% | 12.9% | |||
| 1.8–2.6 | 28.9% | 33.4% | 29.0% | 31.9% | 32.5% | 27.7% | |||
| 2.6–3.4 | 32.7% | 21.4% | 30.7% | 29.1% | 29.3% | 29.4% | |||
| 3.4–4.1 | 16.9% | 13.4% | 17.0% | 13.2% | 14.7% | 18.2% | |||
| 4.1–4.9 | 8.0% | 5.8% | 7.8% | 6.3% | 6.5% | 7.6% | |||
| ≥4.9 | 2.4% | 1.3% | 2.4% | 1.9% | 1.2% | 4.3% |
Abbreviations: CAD, coronary artery disease; CKD, chronic kidney disease; LDL-C, low density lipoprotein-C.
BG Management in Patients with Hypertension
| Non-Diabetes | Diabetes | p | |
|---|---|---|---|
| FBG (mmol/L) | <0.001 | ||
| <5.6 | 54.1% | 11.4% | |
| 5.6–7.0 | 40.5% | 32.4% | |
| ≥7.0 | 5.4% | 56.2% | |
| HbA1c (%) | <0.001 | ||
| <6.5 | 78.3% | 26.2% | |
| 6.5–7.0 | 12.1% | 17.5% | |
| 7.0–8.0 | 2.7% | 25.3% | |
| ≥8.0 | 7.0% | 31.0% |
Abbreviation: FBG, fasting blood glucose.
Body Weight Management in Patients with Hypertension
| Total | Female | Male | p | |
|---|---|---|---|---|
| BMI (kg/m2) | 24.88±4.04 | 24.68±4.40 | 25.05±3.72 | 0.003 |
| BMI | <0.001 | |||
| BMI<25 (kg/m2) | 56.8% | 59.8% | 54.4% | |
| BMI 25–30 (kg/m2) | 36.8% | 33.5% | 39.4% | |
| BMI ≥30 (kg/m2) | 6.4% | 6.7% | 6.2% | |
| Abdominal circumference (cm) | 85.45±14.17 | 82.28±13.34 | 87.96±14.31 | <0.001 |
| Abdominal circumference controlled % | / | 38.7% | 57.9% | <0.001 |
Abbreviation: BMI, body mass index.
Integrated Management of Hypertension in General and Community Hospitals
| Community Hospitals | General Hospitals | p | |
|---|---|---|---|
| Total number | 3039 | 1247 | |
| Age (years) | 67.0±12.3 | 63.0±13.3 | <0.001 |
| Male | 53.6% | 61.8% | <0.001 |
| CAD | 19.8% | 22.5% | 0.06 |
| DM | 21.8% | 23.7% | 0.81 |
| CKD | 14.1% | 9.4% | <0.001 |
| Antihypertensive therapy (%) | 92.8% | 91.8% | 0.23 |
| SBP (mmHg) | 140.0±16.4 | 144.6±20.5 | <0.001 |
| DBP (mmHg) | 82.9±11.9 | 85.6±13.6 | <0.001 |
| BP<140/90 mmHg | 46.6% | 34.5% | <0.001 |
| BP<130/90mmHg | 12.2% | 10.0% | 0.04 |
| ABPM % | 4.9% | 4.2% | 0.34 |
| TC (mmol/L) | 4.91±1.33 | 4.51±1.26 | <0.001 |
| HDL-C (mmol/L) | 1.32±0.33 | 1.16±0.29 | <0.001 |
| TG (mmol/L) | 2.07±1.57 | 1.90±1.45 | 0.02 |
| LDL-C (mmol/L) | 2.92±1.18 | 2.64±0.97 | <0.001 |
| LDL-C in CAD | <0.001 | ||
| <1.8 | 16.7% | 39.7% | |
| 1.8–2.6 | 33.4% | 33.3% | |
| 2.6–3.4 | 25.3% | 14.1% | |
| ≥3.4 | 24.6% | 12.8% | |
| LDL-C in Non-CAD | 0.06 | ||
| <1.8 | 10.2% | 13.4% | |
| 1.8–2.6 | 27.7% | 32.0% | |
| 2.6–3.4 | 34.1% | 29.0% | |
| ≥3.4 | 28.0% | 25.6% | |
| Diabetes | |||
| FBG (mmol/L) | 7.6±2.6 | 8.1±2.9 | 0.039 |
| HbA1c (%) | 7.4±1.9 | 8.2±2.5 | <0.001 |
| Anti-diabetes medication (%) | 89.2% | 85.8% | 0.16 |
| Non-diabetes | |||
| FBG (mmol/L) | 5.6±0.9 | 5.7±1.2 | 0.07 |
| HbA1c (%) | 6.2±1.6 | 6.2±1.8 | 0.86 |
| BMI | 24.7±4.2 | 25.3±3.7 | <0.001 |
Abbreviations: CAD, coronary artery disease; DM, diabetes mellitus; CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; ABPM, arterial blood pressure monitoring; TC, total cholesterol; LDL-C, low density lipoprotein-C; HDL-C, high density lipoprotein-C; TG, triglyceride; FBG, fasting blood glucose; BMI, body mass index.
The Achievement of BP, LDL-C, HbA1c and BMI in General Hospitals Compared to Those in Community Hospitals
| Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| BP (mmHg) | ||||||
| <140/90 | 0.60 (0.52–0.69) | <0.001 | 0.63 (0.55–0.73) | <0.001 | 0.63 (0.55–0.73) | <0.001 |
| <130/80 | 0.80 (0.64–0.99) | 0.044 | 0.86 (0.69–1.07) | 0.182 | 0.85 (0.68–1.06) | 0.138 |
| LDL-C (mmol/L) | ||||||
| <1.8 in CAD | 3.28 (2.11–5.12) | <0.001 | 3.42 (2.13–5.48) | <0.001 | 3.25 (2.02–5.24) | <0.001 |
| <2.6 in DM | 1.4 (0.97–2.04) | 0.076 | 1.57 (1.06–2.33) | 0.024 | 1.57 (1.05–2.34) | 0.026 |
| <2.6 in CKD | 3.05 (1.71–5.46) | <0.001 | 3.04 (1.67–5.52) | <0.001 | 3.13 (1.72–5.71) | <0.001 |
| HbA1c (%) | ||||||
| <6.5 in DM | 0.81 (0.51–1.30) | 0.392 | 0.82 (0.50–1.32) | 0.405 | 0.77 (0.47–1.25) | 0.292 |
| <7.0 in DM | 0.82 (0.55–1.24) | 0.359 | 0.85 (0.56–1.29) | 0.437 | 0.83 (0.54–1.27) | 0.393 |
| <8.0 in DM | 0.59 (0.39–0.91) | 0.016 | 0.63 (0.41–0.97) | 0.037 | 0.64 (0.41–1.00) | 0.052 |
| BMI (kg/m2) | ||||||
| <25 | 0.65 (0.57–0.74) | <0.001 | 0.70 (0.61–0.80) | <0.001 | 0.72 (0.63–0.83) | <0.001 |
Notes: Model 1: unadjusted OR; Model 2: OR adjusted for gender and age; Model 3: OR adjusted for gender, age, anti-hypertensive therapy, statin therapy, anti-hyperglycemia therapy.
Abbreviations: BP, blood pressure; LDL-C, low density lipoprotein-C; CAD, coronary artery disease; DM, diabetes mellitus; CKD, chronic kidney disease; BMI, body mass index.